Karine has 20 years of experience in clinical research operations, in roles with increasing responsibilities. Prior to joining the leadership team, Karine Lalonde was most recently Senior Director, Clinical Operations at Inversago. Previously at Ipsen, following the acquisition of Clementia Pharmaceuticals Inc., she contributed substantially to the NDA of palovarotene. Along her career, Karine acquired extensive experience in broad therapeutic areas ranging from diabetes to oncology and musculoskeletal rare diseases, including pediatric trials. Karine holds a MSc in clinical pharmacology from Université de Montréal.

• 

  Vice-President, Clinical Operations in Inversago Pharma

  Transformative therapies for the treatment of metabolic and fibrotic diseases